P075 Evaluation of the impact of the COVID-19 pandemic on patients with rheumatic diseases in the UK: results from the REUMAVID study
Conclusion The REUMAVID study has allowed us to measure and quantify the experience of British patients with rheumatic disease during an unprecedented public health crisis. A reduction in healthcare access, concern about treatment, changes in daily life habits and worsening of well-being and mental health w ere reported during the first wave. Patient organisations were the main source of COVID-19-related information. Further data will be gathered during the second wave.Disclosure M. Garrido-Cumbrera: None.V. Navarro-Comp án: Honoraria; Abbvie, BMS, Lilly, MSD, Novartis, Pfizer, Roche, UCB.D. Webb: Grants/research support; AbbVie, Biogen, Janssen, Lilly, Novartis, UCB.C. Jacklin: Grants/research support; Abbvie, Amgen, Biogen, Eli, Lilly, Gilead, Janssen, Pfizer, Roche, Sanofi, UCB.S. Irwin: Other; Coronavirus Community Support Fund.L. Christen: Other; Novartis employee.J. Correa-Fern ández: None.S. Sanz-G ómez: None.H. Marzo-Ortega: Honoraria; Abbvie, Celgene, Eli-Lilly, Janssen, Novartis, Pfizer, Takeda, UCB. Grants/research support; Janssen, Novartis.
Source: Rheumatology - Category: Rheumatology Source Type: research
More News: Alcoholism | Anxiety | Arthritis | Coronavirus | COVID-19 | Depression | Grants | Health Management | International Medicine & Public Health | Men | Osteoarthritis | Pandemics | Pfizer | Psychology | Rheumatoid Arthritis | Rheumatology | SARS | Smokers | Sports Medicine | Study | UK Health | Women